



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>4</sup> :  A61K 31/78	A1	(11) International Publication Number: WO 88/ 06888  (43) International Publication Date: 22 September 1988 (22.09.88)
<p>(21) International Application Number: PCT/US87/00584</p> <p>(22) International Filing Date: 20 March 1987 (20.03.87)</p> <p>(71) Applicant: CURATEK PHARMACEUTICALS, INC. [US/US]; 1965 Pratt Boulevard, Suite 101, Elk Grove Village, IL 60007 (US).</p> <p>(72) Inventor: BORGMAN, Robert, John ; 1735 Victoria Road, Mundelein, IL 60060 (US).</p> <p>(74) Agents: FIGG, E., Anthony et al.; Bernard, Rothwell &amp; Brown, 1700 K Street, NW, Suite 800, Washington, DC 20006 (US).</p> <p>(81) Designated States: AT (European patent), AU, BE (European patent), BR, CH (European patent), DE (European patent), DK, FI, FR (European patent), GB (European patent), IT (European patent), JP, KP, KR, LU (European patent), NL (European patent), NO,</p>		<p>SE (European patent).</p> <p>Published <i>With international search report.</i></p>
<p>(54) Title: NOVEL TOPICAL METRONIDAZOLE FORMULATIONS AND THERAPEUTIC USES THEREOF</p> <p>(57) Abstract</p> <p>Novel topical formulations containing the drug metronidazole comprise aqueous single-phase gels. The formulations have improved specific activity and lack the comedogenic, irritant and skin-drying ingredients commonly found in prior art formulations in which the drug is dissolved in an oil phase of the formulation. The aqueous topical formulations are particularly useful for treating rosacea and other acneform dermatological conditions, and certain forms of dermatitis.</p>		

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

NOVEL TOPICAL METRONIDAZOLE FORMULATIONS  
AND THERAPEUTIC USES THEREOF

Background of the Invention

5 Field of the Invention

This invention relates to novel topical formulations containing the drug metronidazole and methods of treating skin disorders using the novel formulations.

Description of the Prior Art

10 Metronidazole, 1-(2-hydroxyethyl)-2-methyl-5-nitroimidazole, is a drug known to be effective in treating a variety of disorders. For example, the drug has direct trichomonacidal and amebacidal activity against Trichomonas vaginalis and Entamoeba histolytica,  
15 and is useful in combatting infections caused by those microbial parasites. Metronidazole has also been reported to be effective (via both oral and topical application) in treating skin disorders such as rosacea, ulcers infected with anaerobic bacteria, including  
20 decubitus ulcers (bed or pressure sores), venous ulcers, and diabetic foot ulcers, and other anaerobic infections such as post operative sepsis. There have also been reports that metronidazole is effective against perioral dermatitis.

25 Although oral administration of the drug has been employed for the treatment of certain disorders, long-term oral administration of the drug in cases of chronic disorders such as rosacea may be associated with

certain unwanted side effects, and subjects all organ systems needlessly to high drug concentrations. Well-known problems associated with systemic antibiotic therapy include gastro-intestinal intolerance and vaginitis. Thus, topical formulations are generally preferred for dermatological applications. (See "Practical Advice offered on Rosacea", Dermatology News, April, 1985).

It is known that the effectiveness of a drug against a particular illness may be profoundly affected by the vehicle into which the drug is incorporated. One difficulty in formulating topical compositions of metronidazole stems from the drug's low solubility in water and several other solvents. Accordingly, the topical preparations described to date for treatment of rosacea generally have been creams (oil in water emulsions) or ointments (petroleum jelly based compositions). In these formulations, the drug is dissolved in the oil phase.

Rosacea, formerly called Acne rosacea, is a chronic skin disease primarily affecting adults, with recurring symptoms that include erythema, papules, pustules, rhinophyma, and telangiectses, primarily in the region of the nose, cheeks, and forehead. The metronidazole-containing topical formulations used to treat rosacea generally contain oils, certain surfactants and emulsifiers, and/or other ingredients which have been found to be comedogenic, acnegenic, and/or irritating to the skin. (See Fulton et al., Amer. Acad. of Dermatology, Vol. 10, no. 1, pp. 96-105, (Jan. 1984)). Patients treated with such formulations therefore often experience skin problems which include irritation, uncomfortable drying of the skin, and "stinging" or "burning" sensations. In addition, the drug is generally dissolved or dispersed in the oil phase of such

preparations, which reduces the specific activity of the drug due to inhibition of drug transfer across the cell membrane. Such effects are described in Nielsen, P., British J. of Dermatology, Vol. 108, pp. 327-332 (1983),  
5 for example.

Thus, a need remains for metronidazole-containing dermatological preparations suitable for topical use which avoid the problems of prior art formulations. Such dermatological preparations would be useful for treating  
10 skin disorders such as rosacea and certain types of dermatitis, including perioral dermatitis.

#### Summary of the Invention

In accordance with the present invention, an aqueous gel composition for topical application consists  
15 essentially of a) a therapeutically effective amount of metronidazole, b) a polycarboxylated vinyl polymer in an amount effective to promote solubility of said metronidazole and to cause gelling of said composition, and c) an aqueous solvent. The single-phase aqueous gels  
20 have higher specific activity of metronidazole compared to prior art oil-based formulations, due to increased bioavailability of the drug when solubilized in an aqueous composition. The compositions comprise non-comedogenic, non-irritating ingredients and thus  
25 avoid problems associated with the use of prior art formulations in the treatment of skin diseases. The aqueous gels of the present invention have properties which make them particularly suitable for the treatment of skin disorders such as rosacea and other acneform  
30 conditions and certain types of dermatitis.

#### Detailed Description of the Invention

Substantially oil-free, aqueous formulations of metronidazole, in which the drug is solubilized in a

single-phase aqueous gel, are disclosed. The advantages of such aqueous formulations in treating skin disorders have been discussed above, and are presented in greater detail below.

5       When developing topical formulations for application to diseased skin, different aspects, such as thermodynamic activity of the drug in the vehicle (base), the release rate of the drug from the vehicle, the type and the status of the skin, and the sensitization and  
10       irritation potential of components are factors that can affect the therapeutic effectiveness of topical dermatological preparations. In the case of non-diseased skin with its intact stratum corneum, cell membrane-controlled penetration of the drug occurs.  
15       Therefore, a high thermodynamic activity of the drug in the vehicle is desirable (low affinity to the vehicle) to promote transfer of the drug across the epidermal cell membranes. With diseased skin, the release rate of the drug from the vehicle generally is rate-determining for  
20       penetration into a patient's cells. Therefore, vehicles which dissolve the drug and have a low diffusional resistance are preferred. In general, drug concentration in the vehicle, and thus the degree of saturation, is considered to be a key formulation factor when optimizing  
25       topical delivery for maximum bioavailability.

      In rosacea (and other acneform conditions) and in certain types of dermatitis, topical formulations are usually applied to both normal and diseased areas. It is therefore desirable that a treatment have a mitigating  
30       effect on the diseased tissue and a prophylactic effect to prevent extension of involvement to the normal areas. Therefore, the most desired vehicle and hence formulation in these conditions should contain the drug in high thermodynamic activity (a high rate of cell membrane  
35       penetration) and with a fast rate of release from the

vehicle. Aqueous formulations of metronidazole would appear to meet the above criteria. The low solubility of metronidazole in water (and in several other solvents), however, has resulted in the development of oil-based, rather than aqueous, metronidazole formulations for treatment of rosacea.

In the formulations of the present invention, metronidazole is dissolved in an aqueous solution of a high molecular weight polycarboxylated vinyl polymer. The polymer serves not only to promote solubility of the drug in water, but also imparts a desirable viscous, gelled consistency to the composition when mixed with the drug and water. The gels (>95% water formulations) of the present invention have the requisite degree of metronidazole concentration and hence thermodynamic activity for effective topical delivery and bioavailability of the drug. The gels of the present invention also have the requisite therapeutic activities as described below. The present invention therefore provides a method for the prophylactic or therapeutic treatment of humans afflicted with such skin disorders as rosacea, other acneform conditions (e.g., acne vulgaris, steroid acne, acne conglobata, or nodulocystic acne) or certain types of dermatitis (e.g., perioral dermatitis or seborrheic dermatitis).

The viscous gelled vehicle also minimizes "pooling" and "running" of the medication, e.g. pooling into facial creases, which sometimes occurs with dermatological cream preparations. The resulting local excesses of the creams may contribute to problematic erythema or stinging. The aqueous gels of the present invention afford more control in application, and better maintenance of a uniform distribution of the drug over the area to be treated, than would generally be expected if the drug were applied as a cream or in an aqueous solution.

The ideal vehicle advantageously functions as a "sustained delivery" system for the drug, in which the drug continuously is delivered to the cells at, or slightly above, a minimum therapeutically effective level which is sustained over a period of time. This mode of drug release from the vehicle is preferred over vehicles which release the drug at levels much higher than the necessary therapeutic level shortly after application to the skin, followed by a sharp decrease to a level which is not therapeutically effective. The aqueous gels of the present invention function as sustained delivery systems, whereas prior art formulations generally do not provide sustained drug delivery at a relatively constant therapeutically effective level over a period of time.

The polymer may be any suitable polymer which is hydrophilic, has free carboxylic groups and high base binding capacity, forms a gel of uniform consistency when neutralized with a base, and is effective in promoting solubility of metronidazole in the resulting gel. Preferred polymers for use in the formulations of the invention are high molecular weight polycarboxylated vinyl polymers, with polyacrylic acid polymers being particularly preferred. The molecular weight of the polymer is desirably between about 1,250,000 and 3,000,000. Suitable polyacrylic acid polymers include, but are not limited to, those commercially available from B.F. Goodrich, Cincinnati, Ohio, under the trademarks Carbopol 934, 940, and 941. Carbopol 940<sup>™</sup> is a particularly preferred polymer for use in this invention.

The polymer is present in an amount sufficient to promote solubility of the drug in water and to cause gelling of the formulation, imparting the desired viscous consistency to the topical formulation. The metronidazole formulations advantageously comprise about



0.2% to about 7.0% by weight of the polymer, preferably about 0.5% to about 1.5%, and most preferably about 0.6% by weight of the polymer.

Aqueous solutions of these polymers are known to  
5 form gels when neutralized with a base. Water-soluble bases which have been used to promote gelling of polymers such as carbopols include organic amines (alkylamines such as methylamine and ethylamine, dialkylamines, trialkylamines, alkanolamines, and  
10 dialkanolamines, among others) and inorganic bases such as an aqueous solution of ammonia. The drug being added to the formulation of the present invention, metronidazole, is sufficiently basic to partially neutralize the acidic polymer in aqueous solution to the  
15 desired degree and to promote gelling.

Metronidazole is employed in the compositions in an effective amount. The actual concentration of the drug may vary, depending on the nature and degree of the disorders being treated, and whether the drug is being  
20 administered for therapeutic or prophylactic purposes. The formulations advantageously comprise from about 0.1% to about 1.5%, preferably about 0.25% to about 1.0%, and most preferably about 0.75% by weight of metronidazole.

Optionally, the formulation may also comprise a  
25 "penetration enhancer", i.e., an agent that promotes penetration of the active drug into the patient's skin or tissues. Such penetration enhancers include but are not limited to, dimethyl sulfoxide (DMSO) and propylene glycol, with the latter being preferred. The composition  
30 advantageously comprises from about 1.0% to about 50%, preferably about 2% to about 5%, and most preferably about 3% by weight of said penetration enhancer.

Preservatives optionally may be incorporated into the compositions in an amount effective for inhibiting  
35 growth of microbes such as yeast and molds in the

composition during storage. Any conventional preservatives may be used, with parabens being preferred. A mixture of methyl paraben and propyl paraben has been found particularly effective as a preservative. Most  
5 preferably, the composition comprises about 0.08% by weight of methyl paraben and about 0.02% by weight of propyl paraben.

Ethylenediaminetetraacetic acid (EDTA) or one of its salts is commonly added to dermatological preparations,  
10 and may optionally be incorporated into the compositions of the present invention. EDTA chelates certain metals that may be present in the formulation, which is useful because some patients have adverse reactions to preparations containing metal impurities. The EDTA will  
15 also inhibit undesirable "browning" of the composition which may occur over time in compositions having low pH (e.g., pH 3.5 to about 5.4). Advantageously, the formulation of the invention comprises from about 0.01% to about 0.1%, preferably about 0.05% by weight of EDTA.

20 The final pH of the formulations of the invention may vary within a physiologically compatible range. Advantageously, the final pH is a physiologically compatible (i.e., not harmful to biological tissue) acidic pH. The pH is preferably between about 3 and  
25 about 6.9, and most preferably between about 4 and 5. Any suitable method of adjusting the pH of aqueous solutions may be used. Advantageously, sodium hydroxide (NaOH) is added to the formulation to bring the final pH to the desired level. Gel formulations of the invention  
30 are more viscous at pH's that approach neutrality than at the more acidic pH's within the preferred range (i.e., viscosity increases as the polymer in the gel is neutralized to greater degrees, e.g. with NaOH).

The ingredients listed above may be combined in any  
35 order and manner that produces a formulation comprising

metronidazole dissolved in (and evenly dispersed throughout) a one-phase aqueous gel of the desired consistency and pH. One suitable method of preparing formulations of the invention involves preparation of an aqueous solution of the polymer, which will be called "Part A". Advantageously, this solution comprises the polymer in distilled water. A "Part B" is prepared comprising metronidazole. Mixing of Parts A and B results in gelling of the composition. The optional penetration enhancer and preservative(s) are preferably included in Part B. If EDTA is to be added to the formulation, it is preferably included in Part A. The pH may then be adjusted to the desired level, e.g., by addition of NaOH.

The resulting homogeneous gels possess the advantageous properties described above, including non-comedogenic, non-acneogenic, and non-irritating ingredients; higher specific activity of metronidazole due to increased diffusion across membranes and release from the vehicle (resulting in greater therapeutic effectiveness using smaller amounts of the drug); and a desirable consistency that prevents undesired pooling and spreading of the drug. High concentrations of skin-drying ingredients (e.g. alcohols and acetone), which are found in some dermatological preparations to promote drug solubility, are also avoided. Such ingredients at high concentration may excessively dry the patient's skin, causing undesirable flaking and discomfort.

The therapeutic effectiveness of the metronidazole formulations of the present invention is demonstrated in the following examples. These examples are meant to illustrate the invention rather than to limit its scope. Variations in the formulations which do not adversely affect the effectiveness of the drug will be evident to

one skilled in the art, and are within the scope of this invention. For example, additional ingredients such as coloring agents, sunscreens, and the like may be included in the formulations as long as the resulting formulation  
5 retains the desirable properties (non-comedogenicity, high specific activity, etc.) described above.

The drug 1-(2-hydroxyethyl)-2-methyl-5-nitroimidazole and various derivatives thereof are described in U.S. Patent No. 2,944,061, incorporated  
10 herein by reference. The term "metronidazole" as used in this application is meant to include not only 1-(2-hydroxyethyl)-2-methyl-5-nitroimidazole, but also those analogs and derivatives of the drug which are solubilized in the gel formulations previously described  
15 and which have therapeutic activity when topically applied.

#### Example I

A 30 kilogram (kg) batch of a formulation of the present invention was prepared as follows. 0.18 kg of  
20 Carbopol 940 (0.6% by weight of the final weight of the formulation) was dissolved in 16.5 liters of distilled water containing 15 g of EDTA disodium dihydrate. Sufficient 10% NaOH was added to bring the pH to about 5. This aqueous polymer solution was called "Part A". "Part  
25 B" was prepared by mixing 0.9 kg of propylene glycol (3% by weight of the final weight) with 24 grams of methyl paraben (0.08% by weight as above), 6.0 grams of propyl paraben (0.02% by weight as above) and adding to 0.225 kg of metronidazole in 11.4 liters of distilled water  
30 maintained at 50°C. Parts A and B were then mixed thoroughly and gelling of the formulation resulted. A cold aqueous solution of NaOH was then used to adjust the final pH to 5.25, and distilled water was added to give

the desired 30 kilogram final weight. The NaOH and water were thoroughly mixed into the viscous gel.

### Example II

A randomized, double blind, placebo controlled clinical trial was conducted to demonstrate the positive clinical efficacy of the aqueous metronidazole-containing gel formulation prepared in Example I in treating rosacea. The study included patients who had received no prior treatment for rosacea, as well as patients who had been treated by conventional methods. Patients discontinued treatment, if any, at least 21 days prior to the start of this study. Each patient received metronidazole in the gel formulation on one side of the face and the formulation gel (placebo control) without metronidazole on the other side of the face. Therefore, in this study, each patient served as their own control.

The effectiveness of the treatment was rated, at the time points indicated in the Tables below, in six different categories, namely, reduction in inflammatory lesions (papules and pustules), erythema, stinging, burning, itching, and dryness. The data are shown in the Tables below.

Table I-A shows the percent reduction in inflammatory lesions (papules and pustules) from baseline values for active (i.e., metronidazole-treated) and placebo-treated sides. Inflammatory lesions were progressively reduced from 46.7% to 59.9% for active-treated sides while placebo-treated sides reflected an exacerbation. There was an 82.6% difference in inflammatory lesions at the end of drug treatment on the metronidazole versus placebo-treated sides.

Table I-B shows mean erythema values for active- and placebo-treated sides. Statistically significant

differences were found at visits 2, 3, 4 and 5 for the active sides and at visits 3 and 4 for the placebo sides, when compared to baseline values. Active- and placebo-side values were significantly different from each other at visits 3, 4 and 5. A concomitant improvement in reduction of erythema was seen at the same time point on the treated side and on the placebo side, both statistically significant from baseline with the metronidazole treated side significantly more improved than the placebo side.

Table II-A shows mean stinging scores for active- and placebo-treated sides. Statistically significant differences were found at visits 3, 4 and 5 for both the active and placebo sides, when compared to baseline values. Active- and placebo-side values were not significantly different from one another.

Table II-B shows mean burning scores for active- and placebo-treated sides. Statistically significant differences were found at all visits (2, 3, 4, 5) for both the active and placebo sides, when compared to baseline values. Active- and placebo-side values were not significantly different from one another.

Table II-C shows mean itching scores for active- and placebo-treated sides. Statistically significant differences were found at all visits (2, 3, 4, 5) for both the active and placebo sides, when compared to baseline values. Active- and placebo-side values were not significantly different from one another.

Table II-D shows mean dryness scores for active- and placebo-treated sides. Statistically significant differences were found at visits 3, 4 and 5 for active sides and at visits 4 and 5 for placebo sides, when compared to baseline values. Active- and placebo-side values were not significantly different from one another.

Tables II-A, II-B, II-C, and II-D show an unexpected but dramatic improvement in local tolerance data. This data represents the patients' subjective assessments of stinging, burning, itching and dryness on each side of their faces before and during drug or placebo treatment. The data shows that there was a dramatic (highly statistically significant) improvement in the patients' perceptions of these attendant complications of the disease. Since both sides improved to the same degree (no statistically significant difference can be found), the improvement apparently comes from the gel formulation per se.

This data confirms the effectiveness of metronidazole in the gel formulation for treatment of acne rosacea and also demonstrates the unique therapeutic effects of the gel formulation.

Table I-A  
Inflammatory Lesions  
(Efficacy Data From 20 Subjects)

	<u>On Drug</u>			<u>Off Drug</u>
	<u>Visit 2</u> <u>Weeks 3-5</u>	<u>Visit 3</u> <u>Weeks 6-8</u>	<u>Visit 4</u> <u>Weeks 9-11</u>	<u>Visit 5</u> <u>Weeks 12-17</u>
<u>Active</u>				
(Percent Reduction from Baseline)				
25	46.7	55.1	59.9	41.6
<u>Placebo</u>				
(Percent Reduction from Baseline)				
30	-22.5	- 4.2	-22.7	-46.8
<u>Difference</u>				
(Active-Placebo Percent Difference)				
35	69.2	59.3	82.6	88.4

Table I-B  
Erythema  
(Efficacy Data From 20 Subjects)

5				On Drug		Off Drug
		Visit 1	Visit 2	Visit 3	Visit 4	Visit 5
			Weeks	Weeks	Weeks	Weeks
		<u>Baseline</u>	<u>3-5</u>	<u>6-8</u>	<u>9-11</u>	<u>12-17</u>
	<u>Active</u>					
10	(Mean Values)	2.10	1.55***	1.05***	1.05***	1.15***
	<u>Placebo</u>					
	(Mean Values)	2.10	1.90	1.55***	1.55***	1.70
15	3=Severe					
	2=Moderate					
	1=Mild					
	0=Absent					
20	*** p<.01 compared to baseline values.					
	<u>Active</u>					
	<u>Versus</u>					
	<u>Placebo</u>					
	<u>Significant</u>					
25	<u>Differences</u>	No	No			
	(p values)	Difference	Difference	p<.02	p<.02	p<.02



Table II-A  
Stinging  
 (Local Tolerance Data from 20 Subjects)

5		Visit 1	On Drug		Off Drug	
			Visit 2	Visit 3	Visit 4	Visit 5
			Weeks	Weeks	Weeks	Weeks
		<u>Baseline</u>	<u>3-5</u>	<u>6-8</u>	<u>9-11</u>	<u>12-17</u>
10	<u>Active</u>					
	(Mean Values)	0.70	0.25	0.15**	0.00***	0.00***
15	<u>Placebo</u>					
	(Mean Values)	0.65	0.30	0.15*	0.20*	0.05***
	3=Severe					
	2=Moderate					
	1=Mild					
	0=Absent					
20	* p<.05 compared to baseline values					
	** p<.02 compared to baseline values					
	*** p<.01 compared to baseline values					
25	<u>Active</u>					
	<u>Versus</u>					
30	<u>Placebo</u>					
	<u>Significant</u>					
	<u>Differences</u>	No	No	No	No	No
	(p values)	Difference	Difference	Difference	Difference	Difference

Table II-B  
Burning  
 (Local Tolerance Data from 20 Subjects)

5		Visit 1	Visit 2	On Drug Visit 3	Visit 4	Off Drug Visit 5
		Baseline	Weeks 3-5	Weeks 6-8	Weeks 9-11	Weeks 12-17
10	<u>Active</u> (Mean Values)	1.25	0.30**	0.10***	0.05***	0.05***
	<u>Placebo</u> (Mean Values)	1.05	0.30***	0.05***	0.10***	0.05***
15	3=Severe 2=Moderate 1=Mild 0=Absent					
20	** p<.02 compared to baseline values *** p<.01 compared to baseline values					
25	<u>Active</u> <u>Versus</u> <u>Placebo</u> <u>Significant</u> <u>Differences</u> (p values)	No Difference	No Difference	No Difference	No Difference	No Difference

Table II-C  
Itching  
 (Local Tolerance Data from 20 Subjects)

	Visit 1 Baseline	Visit 2 Weeks 3-5	On Drug Visit 3 Weeks 6-8	Visit 4 Weeks 9-11	Off Drug Visit 5 Weeks 12-17
5					
	<u>Active</u>				
10	(Mean Values)	1.45	0.55***	0.15***	0.20***
	<u>Placebo</u>				
	(Mean Values)	1.40	0.70***	0.25***	0.20***
15	3=Severe 2=Moderate 1=Mild 0=Absent				
20	*** $p < .01$ compared to baseline values				
	<u>Active</u>				
	<u>Versus</u>				
	<u>Placebo</u>				
	<u>Significant</u>				
25	<u>Differences</u>	No	No	No	No
	(p values)	Difference	Difference	Difference	Difference

Table II-D  
Dryness  
 (Local Tolerance Data from 20 Subjects)

5		Visit 1	Visit 2	On Drug		Off Drug
			Weeks	Visit 3	Visit 4	Visit 5
		Baseline	3-5	Weeks	Weeks	Weeks
				6-8	9-11	12-17
	<u>Active</u>					
10	(Mean					
	Values)	1.45	0.85	0.50***	0.25***	0.25***
	<u>Placebo</u>					
	(Mean					
	Values)	1.40	0.85	0.75	0.20***	0.45***
15	3=Severe					
	2=Moderate					
	1=Mild					
	0=Absent					
	*** p<.01 compared to					
20	baseline values					
	<u>Active</u>					
	<u>Versus</u>					
	<u>Placebo</u>					
	<u>Significant</u>					
25	<u>Differences</u>	No	No	No	No	No
	(p values)	Difference	Difference	Difference	Difference	Difference

Claims:

1. A dermatological preparation for topical application in the form of an aqueous gel composition consisting essentially of a) a therapeutically effective amount of metronidazole, b) a polycarboxylated vinyl polymer in an amount effective to promote solubility of said metronidazole and to cause gelling of said composition, and c) an aqueous solvent, and d) from about 2% to about 5%, by weight of a penetration enhancer, wherein said preparation is substantially free of comedogenic, acneogenic, irritating, and skin-drying ingredients.

2. The composition of claim 1 wherein the concentration of metronidazole is from about 0.1% to about 1.5% by weight.

3. The composition of claim 2 wherein the concentration of metronidazole is from about 0.25% to about 1.0% by weight.

4. The composition of claim 3 wherein the concentration of metronidazole is about 0.75% by weight.

5. The composition of claim 1 wherein said polymer is present in an amount of from about 0.2% to about 7.0% by weight.

6. The composition of claim 5 wherein said polymer is present in an amount of from about 0.5% to about 1.5% by weight.

7. The composition of claim 6 wherein said polymer is present in an amount of about 0.6% by weight.

8. The composition of claim 1 wherein said polymer is a hydrophilic, high-molecular weight polycarboxylated vinyl polymer.

9. The composition of claim 8 wherein said polymer is a polyacrylic acid polymer.

10. The composition of claim 9 wherein the molecular weight of said polymer is from about 1,250,000 to about 3,000,000 daltons.

11. The composition of claim 1 which additionally consists of an effective amount of ethylenediamine-tetraacetic acid (EDTA).

12. The composition of claim 1 wherein the concentration of said penetration enhancer is about 3% by weight.

13. The composition of claim 1 wherein said penetration enhancer is DMSO or propylene glycol.

14. The composition of claim 1 which additionally consists of an effective amount of a preservative.

15. The composition of claim 14 wherein said preservative consists of one or more parabens.

16. The composition of claim 15 wherein said preservative consists of about 0.08% by weight of methyl paraben and about 0.02% by weight of propyl paraben.

17. The composition of claim 1 wherein the pH of said composition is a physiologically compatible acidic pH.

18. The composition of claim 17 wherein said pH is between about 3 and about 6.9.

19. The composition of claim 18 wherein said pH is between about 4 and 5.

20. The composition of claim 1 wherein said aqueous solvent is distilled water.

21. A method for the prophylactic or therapeutic treatment of a human afflicted with a skin disorder, which comprises topically applying an effective amount of a dermatological preparation comprising an aqueous gel composition consisting essentially of a) a therapeutically effective amount of metronidazole, b) a polycarboxylated vinyl polymer in an amount effective to

promote solubility of said metronidazole and to cause gelling of said composition, and c) an aqueous solvent.

22. The method of claim 21 wherein the concentration of metronidazole is from about 0.1% to about 1.5% by weight.

23. The method of claim 22 wherein the concentration of metronidazole is from about 0.25% to about 1.0% by weight.

24. The method of claim 23 wherein the concentration of metronidazole is about about 0.75% by weight.

25. The method of claim 21 wherein said polymer is present in an amount of from about 0.2% to about 7.0% by weight.

26. The method of claim 25 wherein said polymer is present in an amount of from about 0.5% to about 1.5% by weight.

27. The method of claim 26 wherein said polymer is present in an amount of about 0.6% by weight.

28. The method of claim 21 wherein said polymer is a hydrophilic, high-molecular weight polycarboxylated vinyl polymer.

29. The method of claim 28 wherein said polymer is a polyacrylic acid polymer.

30. The method of claim 29 wherein the molecular weight of said polymer is from about 1,250,000 to about 3,000,000 daltons.

31. The method of claim 21 wherein said composition additionally consists of an effective amount of ethylenediamine-tetraacetic acid (EDTA).

32. The method of claim 21 wherein said composition additionally consists of a penetration enhancer.

33. The method of claim 32 wherein the concentration of said penetration enhancer is from about 2% to about 5% by weight.

34. The method of claim 33 wherein the concentration of said penetration enhancer is about 3% by weight.

35. The method of claim 32 wherein said penetration enhancer is DMSO or propylene glycol.

36. The method of claim 21 wherein said composition additionally consists of an effective amount of a preservative.

37. The method of claim 36 wherein said preservative consists of one or more parabens.

38. The method of claim 37 wherein said preservative consists of about 0.08% by weight of methyl paraben and about 0.02% by weight of propyl paraben.

39. The method of claim 21 wherein the pH of said composition is a physiologically compatible acidic pH.

40. The method of claim 39 wherein said pH is between about 3 and about 6.9.

41. The method of claim 40 wherein said pH is between about 4 and 5.

42. The method of claim 21 wherein said aqueous solvent is distilled water.

43. The method of claims 21, 22, 25, 28, 31, 32, 36, 39 or 42 wherein said skin disorder is rosacea.


44. The method of claims 21, 22, 25, 28, 31, 32, 36, 39 or 42 wherein said skin disorder is acne vulgaris.

45. The method of claims 21, 22, 25, 28, 31, 32, 36, 39 or 42 wherein said skin disorder is chosen from steroid acne, acne conglobata, nodulocystic acne, perioral dermatitis, and seborrheic dermatitis.



# INTERNATIONAL SEARCH REPORT

International Application No **PCT/US87/00584**

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>1</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC <b>INT. CL(4): A61K 31/78</b> <b>U.S. CL : 424/81</b>		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>4</sup>		
Classification System	Classification Symbols	
U.S.	424/81; 514/398, 514/859, 514/944	
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched <sup>6</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT</b> <sup>14</sup>		
Category <sup>15</sup>	Citation of Document, <sup>16</sup> with indication, where appropriate, of the relevant passages <sup>17</sup>	Relevant to Claim No. <sup>18</sup>
Y	US,A, 4,247,547, (MARKS) 27 January 1981, See entire document.	1-45
Y	US,A, 3,883,661, (YOUNG) 13 May 1975, See entire document.	1-45
Y	P.G. NIELSEN, "A Double-Blind Study Of 1% Metronidazole Cream Versus Systemic Oxytetracycline Therapy For Rosacea", Volume 109, published 1983, by British Journal Of Dermatology, see pages 63-65.	1-45
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p><sup>15</sup> * Special categories of cited documents: <sup>16</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the International filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the International filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p> </div> </div>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search <sup>1</sup>		Date of Mailing of this International Search Report <sup>1</sup>
19 May 1987		27 MAY 1987
International Searching Authority <sup>1</sup>		Signature of Authorized Officer <sup>10</sup>
ISA/US		 Leonard Schenkman

THIS PAGE BLANK (ISPTC)